Compare Hyatt Hotels Corporation (H) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hyatt Hotels Corporation vs Spyre Therapeutics Inc. Common Stock — how do they compare? Hyatt Hotels Corporation trades at $160.32 (market cap $15.35B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Hyatt Hotels Corporation is far larger — about 2× Spyre Therapeutics Inc. Common Stock's market cap, and Hyatt Hotels Corporation pays a 0.37% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hyatt Hotels Corporation for 149 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| H | SYRE | |
|---|---|---|
Market Cap | $15.35B | $7.52B |
Volume | 614,954 | 1,441,031 |
Sector | Consumer Cyclical | Health |
52-Week High | $202.09 | $108.92 |
52-Week Low | $135.42 | $22.18 |
Typical Hold Time | 149 Days | 0 Days |
Enterprise Value | $19.26B | $6.52B |
Dividend Yield | 0.37% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hyatt Hotels Corporation (H) trades at $160.32, down 0.53% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows a high P/E ratio of 201.14 but benefits from a strategic collaboration with Delta Air Lines and portfolio expansion. Cash flow trends indicate variability, with a net cash outflow of $227 million in 2025, while revenue grew to $7.10 billion.
The outlook is mixed: analyst consensus is a Moderate Buy with a $197.92 price target, implying 23% upside, but risks include high valuation, debt levels, and net income volatility. Growth drivers include brand expansion and loyalty partnerships, yet investors should monitor execution on profitability and macroeconomic impacts on travel demand.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
